FDA Approves Viltolarsen, Now Viltepso, for DMD Patients With Exon 53 Mutation
The U.S. Food and Drug Administration (FDA) has conditionally approved NS Pharma‘s Viltepso (viltolarsen) for people with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping…